TransMedics Group, Inc. (TMDX)
| Market Cap | 3.20B -21.5% |
| Revenue (ttm) | 727.65M +28.5% |
| Net Income | 144.45M +57.4% |
| EPS | 3.88 +52.8% |
| Shares Out | 34.73M |
| PE Ratio | 23.74 |
| Forward PE | 40.99 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 915,007 |
| Open | 90.95 |
| Previous Close | 90.95 |
| Day's Range | 90.00 - 93.46 |
| 52-Week Range | 60.11 - 156.00 |
| Beta | 2.10 |
| Analysts | Buy |
| Price Target | 104.55 (+13.63%) |
| Earnings Date | Nov 5, 2026 |
About TMDX
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung tra... [Read more]
Financial Performance
In 2025, TransMedics Group's revenue was $605.49 million, an increase of 37.13% compared to the previous year's $441.54 million. Earnings were $190.29 million, an increase of 436.58%.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for TMDX stock is "Buy." The 12-month stock price target is $104.55, which is an increase of 13.63% from the latest price.
News
TransMedics Group Transcript: Stifel 2026 Healthcare Conference 2026
OCS 2.0 trials target better heart and lung outcomes and expanded utilization, while European logistics and NOP are expected to build revenue from H2 2027. Kidney and transplant services offer additional growth avenues; initial 2027 guidance is expected to include 20%–25% growth.
TransMedics price target raised to $88 from $77 at UBS
UBS analyst Patrick Wood raised the firm’s price target on TransMedics (TMDX) to $88 from $77 and keeps a Neutral rating on the shares.
TransMedics price target raised to $120 from $95 at Canaccord
Canaccord analyst William Plovanic raised the firm’s price target on TransMedics (TMDX) to $120 from $95 and keeps a Buy rating on the shares. The firm said its guidance was…
TransMedics price target raised to $85 from $73 at JPMorgan
JPMorgan raised the firm’s price target on TransMedics (TMDX) to $85 from $73 and keeps a Neutral rating on the shares.
TransMedics price target raised to $70 from $65 at Stifel
Stifel raised the firm’s price target on TransMedics (TMDX) to $70 from $65 and keeps a Hold rating on the shares.
TransMedics price target raised to $117 from $110 at Baird
Baird raised the firm’s price target on TransMedics (TMDX) to $117 from $110 and keeps an Outperform rating on the shares.
TransMedics Group Earnings Call Transcript: Q3 2026
Q3 revenue reached a record $203M, up 41% YoY, with liver and heart share gains and service growth offsetting seasonality. FY 2026 revenue guidance rose to $764M-$774M, while clinical and European expansion programs set up growth catalysts for 2027.
TransMedics Group Earnings release: Q3 2026
TransMedics Group released its Q3 2026 earnings on November 5, 2026, summarizing the period's financial results.
TransMedics Group Quarterly report: Q3 2026
TransMedics Group has published its Q3 2026 quarterly earnings report on November 5, 2026.
TransMedics Group Slides: Q3 2026
TransMedics Group has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 5, 2026.
TransMedics reports Q3 adjusted EPS 51c, consensus 29c
Reports Q3 revenue $203.0M, consensus $177.11M. “Q3 of 2026 was the strongest in TransMedics (TMDX)’ history, with record revenue and record case volume. Importantly, we delivered these results despit...
TransMedics Reports Third Quarter 2026 Financial Results
Strong Revenue Generation Drives Increase in Full-Year 2026 Guidance; Recent Progress Positions Company for Continued Growth with Several Near- and Mid-Term Catalysts ANDOVER, Mass., Nov. 5, 2026 /PRN...
TMDX Investors Have Opportunity to Join TransMedics Group, Inc. Fraud Investigation with SBS Law
LOS ANGELES--(BUSINESS WIRE)---- $TMDX--TMDX Investors Have Opportunity to Join TransMedics Group, Inc. Fraud Investigation with SBS Law.
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANDOVER, Mass., Oct. 30, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-s...
TransMedics to Present at Upcoming Investor Conferences
ANDOVER, Mass., Oct. 29, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-s...
Gogo selected by TransMedics to equip fleet
Gogo (GOGO) announced that TransMedics (TMDX) has selected Gogo Galileo to equip its growing fleet of 22 Embraer Phenom 300E aircraft operating across the United States. The aircraft play a…
TransMedics to Report Third Quarter 2026 Financial Results on November 5, 2026
ANDOVER, Mass., Oct. 22, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-s...
TransMedics price target lowered to $94 from $95 at Canaccord
Canaccord lowered the firm’s price target on TransMedics (TMDX) to $94 from $95 and keeps a Buy rating on the shares. The firm raised its Q3 earnings estimates ahead of…
TransMedics initiated with an Overweight at Barclays
Barclays initiated coverage of TransMedics (TMDX) with an Overweight rating and $120 price target The firm rolled out coverage of the medical suppliers and devices group with a Positive rating.
Did TransMedics Group, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no costor obligation. We would handle any matter on a contingent fee basis, whereby you would notbe responsible f...
TransMedics Group Transcript: 2026 Global Healthcare Conference
The company highlighted robust growth, advanced technology, and a vertically integrated service model, with major expansion plans in heart, lung, and kidney transplants, and a strategic push into Europe. Long-term financial targets remain unchanged, and 2027 is expected to be a pivotal growth year.
TransMedics Group Slides: FY 2026
TransMedics Group has posted slides in relation to its FY 2026 quarterly earnings report, which was published on September 15, 2026.
TransMedics Group Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The discussion highlighted ambitious growth targets, with plans to double U.S. NOP cases by 2030, expand internationally, and launch new organ programs, especially kidney. Investments in logistics, automation, and clinical innovation are expected to drive both market share and overall transplant volume growth.
TransMedics Group Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of TransMedics Group, Inc. - TMDX
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced...
TransMedics appoints Fernando Araujo as CFO
TransMedics (TMDX) appointed Fernando Araujo as CFO, effective September 21. Araujo brings more than 20 years of public-company finance leadership at GE HealthCare, General Electric, and 3M. He succee...